Foghorn therapeutics provides second quarter 2022 financial and corporate update

- fhd-286 dose escalation phase 1 study in metastatic uveal melanoma continues to progress per protocol; working to resolve partial clinical hold in aml and mds
FHTX Ratings Summary
Quant
FHTX Quant Ranking
Sector
Industry
Quant Rating
Quant Score